![]() |
|
|
Vol. 281, Issue 3, 1284-1293, 1997
Pharmaceutical R&D Division, Recordati S.p.A., 20148 Milano, Italy
(R.T., L.G., P.A., E.P., C.T., G.S., D.C., A.L.) and
Department of
Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia,
Pennsylvania (A.C.S., D.P.N., J.P.H.)
The aim of the present work was to investigate whether or not the
uroselectivity of Rec 15/2739 and several other alpha-1 adrenoceptor (
1-AR) antagonists observed in the
anesthetized dog could be related to selectivity of these compounds for
a particular alpha-1 AR subtype. The binding affinity of
the tested compounds for canine prostate alpha-1 ARs and
their in vitro functional affinity for the
alpha-1 ARs of rabbit urethra and prostate correlated with their functional affinity for the alpha-1L AR
subtype, but not with the binding affinity for recombinant animal and
human alpha-1a, alpha-1b and
alpha-1d AR subtypes. Similar results were obtained when
the in vivo potency on urethral pressure was correlated with the affinity for the alpha-1 AR subtypes; also in
this case alpha-1L AR gave the best correlation. No
correlation was obtained by considering the other
alpha-1 AR subtypes. The in vivo
hypotensive effects observed in dog after i.v. administration of the
considered compounds correlated only with the binding affinity for the
animal and human alpha-1d subtype. In conclusion, the
results shown in the present paper indicate that the potencies of
different alpha-1 antagonists against the contractions
induced by norepinephrine on tissues of the lower urinary tract of
rabbits and dogs are better correlated with their affinity for the
putative alpha-1L subtype than for the
alpha-1a subtype. Only the compounds showing selectivity
for the alpha-1L subtype versus the
alpha-1d subtype proved highly selective in
vivo for the lower urinary tract versus the
vascular tissues.
This article has been cited by other articles:
![]() |
D. Marti, R. Miquel, K. Ziani, R. Gisbert, M. D. Ivorra, E. Anselmi, L. Moreno, V. Villagrasa, D. Barettino, and P. D'Ocon Correlation between mRNA levels and functional role of {alpha}1-adrenoceptor subtypes in arteries: evidence of {alpha}1L as a functional isoform of the {alpha}1A-adrenoceptor Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1923 - H1932. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hiraizumi-Hiraoka, T. Tanaka, H. Yamamoto, F. Suzuki, and I. Muramatsu Identification of {alpha}-1L Adrenoceptor in Rabbit Ear Artery J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 995 - 1002. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Hancock, S. A. Buckner, M. E. Brune, T. A. Esbenshade, L. M. Ireland, S. Katwala, I. Milicic, M. D. Meyer, J. F. Kerwin Jr., and M. Williams Preclinical Pharmacology of Fiduxosin, a Novel alpha 1-Adrenoceptor Antagonist with Uroselective Properties J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 478 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sironi, D. Colombo, E. Poggesi, A. Leonardi, R. Testa, O. Rampin, J. Bernabé, and F. Giuliano Effects of Intracavernous Administration of Selective Antagonists of alpha 1-Adrenoceptor Subtypes on Erection in Anesthetized Rats and Dogs J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 974 - 981. [Abstract] [Full Text] |
||||
![]() |
E. E. Daniel, R. D. Brown, Y. F. Wang, A. M. Low, H. Lu-Chao, and C.-Y. Kwan alpha -Adrenoceptors in Canine Mesenteric Artery Are Predominantly 1A Subtype: Pharmacological and Immunochemical Evidence J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 671 - 679. [Abstract] [Full Text] |
||||
![]() |
O. Rossier, L. Abuin, F. Fanelli, A. Leonardi, and S. Cotecchia Inverse Agonism and Neutral Antagonism at alpha 1a- and alpha 1b-Adrenergic Receptor Subtypes Mol. Pharmacol., November 1, 1999; 56(5): 858 - 866. [Abstract] [Full Text] |
||||
![]() |
K. Akiyama, M. Hora, S. Tatemichi, N. Masuda, S. Nakamura, R. Yamagishi, and M. Kitazawa KMD-3213, a Uroselective and Long-Acting alpha 1a-Adrenoceptor Antagonist, Tested in a Novel Rat Model J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 81 - 91. [Abstract] [Full Text] |
||||
![]() |
Y. Fukuta, Y. Fukuda, R. Higashino, K. Yoshida, M. Ogishima, H. Tamaki, and M. Takei Z-350, A Novel Compound with alpha 1-Adrenoceptor Antagonistic and Steroid 5alpha -Reductase Inhibitory Actions: Pharmacological Properties In Vivo J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1013 - 1018. [Abstract] [Full Text] |
||||
![]() |
A. M. Low, H. Lu-Chao, Y. F. Wang, R. D. Brown, C. Y. Kwan, and E. E. Daniel Pharmacological and Immunocytochemical Characterization of Subtypes of Alpha-1 Adrenoceptors in Dog Aorta J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 894 - 901. [Abstract] [Full Text] |
||||